Clinical Trials

150 enrolled

Carcinoma, Hepatocellular

NCT07466238 2026-03-12

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

40 enrolled

Biliary Tract Neoplasms

NCT07457099 2026-03-09

Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

85 enrolled

Head & Neck

Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07453342 2026-03-06

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

500 enrolled

Immune-Related Adverse Events

NCT07434518 2026-02-25

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

500 enrolled

Small Cell Lung Carcinoma

NCT04913311 2026-02-19

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07389876 2026-02-05

G/GEJ

250 enrolled

Stomach Neoplasms

NCT06283238 2026-01-29

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

Withdrawn

GastroEsophageal Cancer

NCT07249060 2025-12-03

INTER-AUTENTIC

300 enrolled

Lupus Erythematosus, Systemic, Myositis, Scleroderma, Systemic, Sjogren's Syndrome

NCT07100405 2025-08-17

TASK-01-RW

50 enrolled

Carcinoma, Hepatocellular

NCT06980350 2025-07-29

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

156 enrolled

Colorectal Neoplasms

NCT05486650 2025-07-14

An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07036016 2025-06-25

Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

67,818 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07009600 2025-06-06

Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

124 enrolled

Stomach Neoplasms

NCT04977791 2025-05-22

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03868046 2025-04-01

AUTENTIC

242 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06900686 2025-03-28

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

458 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colonic Neoplasms, Rectal Neoplasms

NCT05713994 2025-03-25

CCGLC-001

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

600 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT06869239 2025-03-11

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

65 enrolled

Small Cell Lung Carcinoma

NCT03695952 2025-01-28

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

Active not recruiting

100 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06751108 2024-12-27

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active not recruiting

2,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06730503 2024-12-12

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active not recruiting

97 enrolled

Carcinoma, Hepatocellular

NCT06522542 2024-07-26

Gastric Cancer Complicated With Bleeding

Stomach Neoplasms

NCT06505486 2024-07-17

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

21 enrolled

Cholangiocarcinoma

NCT04807114 2024-07-01

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

70 enrolled

Lung Diseases, Interstitial

NCT06464601 2024-06-18

A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer

70 enrolled

Stomach Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Breast

Hypersensitivity, Triple Negative Breast Neoplasms

NCT05934214 2024-03-05

EXIT

141,630 enrolled

Tumor-Agnostic

Neoplasms

NCT06202781 2024-01-12

Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

28 enrolled

Stomach Neoplasms

NCT06031376 2023-09-11

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

106 enrolled

Colorectal Neoplasms

NCT06011330 2023-08-30

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

70 enrolled

Colorectal Neoplasms

NCT05942768 2023-07-12

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

103 enrolled

Metastatic Colorectal Adenocarcinoma

NCT05913583 2023-06-22

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

160 enrolled

Carcinoma, Hepatocellular

NCT05609695 2023-01-31

Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma

100 enrolled

Carcinoma, Hepatocellular

NCT05535998 2022-09-10

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

743 enrolled

Carcinoma, Hepatocellular

NCT05307926 2022-09-07

Postoperative Adjuvant Therapy of HCC Based on PD-1

573 enrolled

Carcinoma, Hepatocellular

NCT05489692 2022-08-10

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

43 enrolled

Cholangiocarcinoma

NCT05326906 2022-05-16

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

20 enrolled

Lung Neoplasms

NCT04922541 2021-06-10

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

50 enrolled

Plaque, Atherosclerotic

NCT04913896 2021-06-04

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Stomach Neoplasms

NCT04835025 2021-04-08

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Suspended

Carcinoma, Non-Small-Cell Lung

NCT04137588 2021-02-24

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

126 enrolled

Advanced Non-squamous Non-small Cell Lung Cancer

NCT04419441 2020-09-16

ICI-RT-1

12 enrolled

Lymphoid

Hodgkin Disease

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04355806 2020-04-21

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

160 enrolled

Carcinoma, Non-Small-Cell Lung, Influenza, Human

NCT03492242 2019-09-26

CHIMeRA